Maze Therapeutics (MAZE) Assets Average (2025 - 2026)
Maze Therapeutics (MAZE) reported Assets Average of $408.4 million for Q1 2026, up 42.46% on a YoY basis from $286.7 million in Q1 2025, and little changed sequentially from $409.6 million in Q4 2025.
Maze Therapeutics (MAZE) Assets Average (2025 - 2026) Analysis & Trends
Maze Therapeutics (MAZE) has 2 years of Assets Average data on file, last reported at $408.4 million in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 42.46% year-over-year to $408.4 million; the trailing twelve-month figure through Mar 2026 stood at $408.4 million (up 42.46% YoY), and the FY2025 full-year result was $318.8 million, changed N/A from the prior year.
- Assets Average was little changed at $408.4 million in Q1 2026, from $409.6 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $409.6 million in Q4 2025 to a low of $286.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 303.40 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 65.01 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 8.37 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 41.64 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 26.06 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 40.71 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 795.91 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.30 Bn |
| 10 | Maze Therapeutics | 1.49 Bn | 1.49 Bn | 18.21 Mn | 408.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 408.42 Mn |
| Dec 31, 2025 | 409.59 Mn |
| Sep 30, 2025 | 362.79 Mn |
| Jun 30, 2025 | 318.18 Mn |
| Mar 31, 2025 | 286.69 Mn |